Compare · HUMA vs MRNA
HUMA vs MRNA
Side-by-side comparison of Humacyte Inc. (HUMA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUMA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $94.42B, about 773.3x HUMA ($122.1M).
- MRNA has been more active in the news (10 items in the past 4 weeks vs 9 for HUMA).
- MRNA has more recent analyst coverage (25 ratings vs 12 for HUMA).
- Company
- Humacyte Inc.
- Moderna Inc.
- Price
- -
- -
- Market cap
- $122.1M
- $94.42B
- 1M return
- -
- +37.67%
- 1Y return
- -
- +699.23%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 9
- 10
- Recent ratings
- 12
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest HUMA
- Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
- Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
- SEC Form 4 filed by Humacyte Inc.
- SEC Form 4 filed by Humacyte Inc.
- Barclays initiated coverage on Humacyte with a new price target
- New insider Kuznik Paul Brian claimed ownership of 222,238 shares (SEC Form 3)
- SEC Form 3 filed by new insider Coward D Scott
- Humacyte Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
- Director Jones Keith Anthony bought $5,620 worth of shares (10,000 units at $0.56), increasing direct ownership by 25% to 50,000 units (SEC Form 4)
Latest MRNA
- SEC Form 4 filed by Moderna Inc.
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
- SEC Form 4 filed by Moderna Inc.
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 3 filed by Moderna Inc.
- Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
- Moderna downgraded by Citigroup with a new price target
- Moderna Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Moderna Adds Chief Operating Officer Role as Company Expands into Oncology